Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

E. Giovannetti, P.A. Zucali, Y.G. Assaraf, L.G. Leon, K Smid, C. Alecci, F. Giancola, A. Destro, L. Gianoncelli, E. Lorenzi, M. Roncalli, A. Santoro, G.J. Peters

Research output: Contribution to journalArticleAcademicpeer-review

25 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)1542-1553
JournalBritish Journal of Cancer
Volume105
Issue number10
DOIs
Publication statusPublished - 2011

Cite this

Giovannetti, E. ; Zucali, P.A. ; Assaraf, Y.G. ; Leon, L.G. ; Smid, K ; Alecci, C. ; Giancola, F. ; Destro, A. ; Gianoncelli, L. ; Lorenzi, E. ; Roncalli, M. ; Santoro, A. ; Peters, G.J. / Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. In: British Journal of Cancer. 2011 ; Vol. 105, No. 10. pp. 1542-1553.
@article{63ddadc17af34879b61e9074f3e1d091,
title = "Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin",
author = "E. Giovannetti and P.A. Zucali and Y.G. Assaraf and L.G. Leon and K Smid and C. Alecci and F. Giancola and A. Destro and L. Gianoncelli and E. Lorenzi and M. Roncalli and A. Santoro and G.J. Peters",
year = "2011",
doi = "10.1038/bjc.2011.400",
language = "Undefined/Unknown",
volume = "105",
pages = "1542--1553",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

Giovannetti, E, Zucali, PA, Assaraf, YG, Leon, LG, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A & Peters, GJ 2011, 'Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin' British Journal of Cancer, vol. 105, no. 10, pp. 1542-1553. https://doi.org/10.1038/bjc.2011.400

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. / Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Leon, L.G.; Smid, K; Alecci, C.; Giancola, F.; Destro, A.; Gianoncelli, L.; Lorenzi, E.; Roncalli, M.; Santoro, A.; Peters, G.J.

In: British Journal of Cancer, Vol. 105, No. 10, 2011, p. 1542-1553.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

AU - Giovannetti, E.

AU - Zucali, P.A.

AU - Assaraf, Y.G.

AU - Leon, L.G.

AU - Smid, K

AU - Alecci, C.

AU - Giancola, F.

AU - Destro, A.

AU - Gianoncelli, L.

AU - Lorenzi, E.

AU - Roncalli, M.

AU - Santoro, A.

AU - Peters, G.J.

PY - 2011

Y1 - 2011

U2 - 10.1038/bjc.2011.400

DO - 10.1038/bjc.2011.400

M3 - Article

VL - 105

SP - 1542

EP - 1553

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -